RNAi Drug Expansion in the Nordics: Genesis Pharma and Alnylam are widening their RNA interference therapeutics partnership to cover Denmark, Finland, Norway, and Sweden, adding to existing reach that already includes Slovenia and the wider Southeast Europe region—aimed at commercializing treatments for serious cardiomyopathy and rare genetic diseases. Peanut Allergy Risk Markers: A Slovenian multicenter study in children with peanut allergy reports that those who had anaphylaxis show stronger skin prick test reactions, higher peanut-specific IgE, and greater basophil activation; lower test responses were linked with later tolerance. Cancer Treatment Tech Deal: Cosylab and Heron Neutron Medical Corp. signed a letter of intent to support global deployment of accelerator-based boron neutron capture therapy (AB-BNCT), focusing on software integration and market access. Slovenia’s Health Digital Push: The European Commission approved Slovenia’s sixth Recovery and Resilience Facility payment (€41m), citing progress including telemedicine upgrades and digital healthcare functions. Youth Mental Health & Inequality: A European study links adolescent psychotropic drug use to gender and economic parity, with girls in lower-parity countries more likely to be higher consumers as depression and anxiety cases rise.